Position Statements

Below you will find HOPA positions as expressed in issue briefs, position statements, and letters.

The Value of Oncology Pharmacists Op-Ed

With Drug Shortages and Errors on the Rise, Oncology Pharmacists are Vital to Navigate Treatment in the Era of a Pandemic. Drug shortages and medication errors are continual issues for cancer patients, with shortages preventing patients from obtaining the care they need and errors contributing to dire consequences for patients. View the full position statement here.

Ensuring Healthcare Worker Safety When Handling Hazardous Drugs

The Hematology/Oncology Pharmacy Association and Oncology Nursing Society have partnered to develop a joint position statement in advance of an upcoming compliance deadline for United States Pharmacopeia (USP) <800>. Titled “Ensuring Healthcare Worker Safety When Handling Hazardous Drugs,” the joint position statement is consistent with USP <800>, National Institute for Occupational Safety and Health (NIOSH), Occupational Safety and Health Administration (OSHA), and American Society of Health-System Pharmacists (ASHP) recommendations. View the full position statement here.


HOPA Issues Principles of Healthcare Reform

View HOPA's position statement  Principles of Healthcare Reform.

HOPA Issues Statement on First Approved Biosimilar in the United States

HOPA is encouraged by the Food and Drug Administration's (FDA) approval of the first biosimilar product, Zarxio (filgrastim-sndz), in the United States, but strongly urges the FDA to develop a naming policy for approved biosimilars.

View the HOPA Biosimilars Issue Brief, or read the Oncology Nursing Society press release regarding the meeting of Safe Handling of Hazardous Drugs Association Stakeholders.